11:13:09 EDT Mon 20 May 2024
Enter Symbol
or Name
USA
CA



Login ID:
Password:
Save

Q:ATAI - ATAI LIFE SCIENCES NV - http://www.ata.net.cn
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
ATAI - Q3.81.73·1.742.81.735+0.0251.5511.28151,1861.80  1.85  1.692.85  1.02510:52:44May 1515 min RT 2¢

Recent Trades - Last 10 of 1186
Time ETExPriceChangeVolume
10:52:44Q1.7350.025100
10:52:27Q1.7350.02523
10:52:16Q1.7320.0221
10:52:02Q1.7350.02550
10:51:34Q1.7350.025100
10:51:32Q1.73980.02985
10:50:58Q1.730.02700
10:50:58Q1.730.02100
10:50:58Q1.730.02100
10:50:58Q1.730.02200

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-05-15 07:00U:ATAINews Releaseatai Life Sciences Reports First Quarter 2024 Financial Results and Corporate Updates
2024-04-24 07:01U:ATAINews Releaseatai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech's Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant Depression
2024-04-17 07:00U:ATAINews Releaseatai Life Sciences Announces the Publication of Beckley Psytech's Phase 1 Study of BPL-003 in the Journal of Psychopharmacology
2024-03-28 07:00U:ATAINews Releaseatai Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate and Clinical Highlights
2024-03-27 07:01U:ATAINews Releaseatai Life Sciences Announces Positive Initial Results from Beckley Psytech's Phase 2a Open Label Study of BPL-003 (Intranasal 5-MeO-DMT) in Treatment Resistant Depression
2024-03-12 12:36U:ATAINews Releaseatai Life Sciences advances VLS-01 for treatment-resistant depression
2024-03-04 08:00U:ATAINews Releaseatai Life Sciences Announces First Participant Dosed in Phase 1b Trial of VLS-01
2024-02-28 17:00U:ATAINews Releaseatai Life Sciences to Participate in the Upcoming TD Cowen 44th Annual Health Care Conference
2024-02-06 17:01U:ATAINews Releaseatai Life Sciences Appoints Anne Johnson as Chief Financial Officer
2024-01-04 07:00U:ATAINews Releaseatai Life Sciences Announces Strategic Investment in Beckley Psytech to Accelerate the Clinical Development of Short-Duration Psychedelics
2024-01-02 08:00U:ATAINews Releaseatai Life Sciences Announces Positive Topline Results from Single Ascending Dose Phase 1 Study with EMP-01 (R-MDMA)
2023-11-14 07:03U:ATAINews Releaseatai Life Sciences Reports Third Quarter 2023 Financial Results and Pipeline Highlights
2023-10-10 08:00U:ATAINews ReleaseATAI LIFE SCIENCES ANNOUNCES FILING OF EARLY WARNING REPORT
2023-10-06 16:05U:ATAINews Releaseatai Life Sciences to Participate in the Jefferies Inaugural Biotech CNS/Neuro Summit
2023-10-02 16:13U:ATAINews Releaseatai Life Sciences Announces Completion of Phase 1 Study of VLS-01 ‚  in Healthy Participants
2023-09-14 08:02U:ATAINews Releaseatai Life Sciences to Participate in the 2023 Cantor Fitzgerald Global Healthcare Conference
2023-09-06 16:01U:ATAINews Releaseatai Life Sciences to Participate in Upcoming September Investor Conferences
2023-08-10 06:59U:ATAINews Releaseatai Life Sciences Reports Second Quarter 2023 Financial Results and Operational Highlights, and Announces Clinical Data from the Phase 1 Study of DMX-1002 (Ibogaine)
2023-08-08 16:02U:ATAINews Releaseatai Life Sciences Announces Results ‚  from the Phase 1 IV-to-Subcutaneous Bridging Study of PCN-101 (R-Ketamine)
2023-06-01 09:10U:ATAINews ReleaseAtossa Appoints Life Sciences Financial and Operations Industry Veteran Greg Weaver as Chief Financial Officer